US-Developed Medical Tech Deployed to Ukraine's Frontlines

RICHMOND, VA – January 21, 2026 – In a move that bridges advanced military research with urgent humanitarian need, a new generation of American-developed medical technology is being deployed to the frontlines in Ukraine. NIRSense, Inc., a Virginia-based med-tech firm, in partnership with the global expeditionary healthcare provider Aspen Medical USA (AMUSA), has donated 12 portable tissue-ischemia monitoring kits to the Ministry of Defence of Ukraine for immediate use in Role-1 and Role-2 casualty care facilities.

These investigational systems are designed to give military medics a critical, real-time view into the oxygenation levels of injured tissue, a capability that could prove decisive in saving limbs and lives amidst the ongoing conflict. The donation represents more than just aid; it is a strategic field evaluation of technology poised to reshape combat casualty care doctrine for Ukraine and its allies.

A New Tool for Life-or-Limb Decisions

On the modern battlefield, extremity injuries are common, and the tourniquet is a ubiquitous life-saver, stopping catastrophic bleeding. However, its application begins a countdown against irreversible tissue damage due to lack of blood flow and oxygen. Medics face the agonizing challenge of determining how long a tourniquet can remain in place without sacrificing the limb. Traditional vital signs and standard pulse oximetry, which measures oxygen in the blood, often fail to provide a clear picture of the health of the tissue below the tourniquet.

This is the critical gap the NIRSense technology aims to fill. Using non-invasive Near-Infrared Spectroscopy (NIRS), the portable consoles and sensors provide continuous data on tissue oxygen saturation (StO2). This allows clinicians to objectively assess tissue perfusion and viability in real time. The technology, which the company calls “Total Oximetry™,” offers actionable data that can inform high-stakes decisions: when to remove a tourniquet, how to manage reperfusion to avoid secondary injury, and how to prioritize casualties for evacuation.

“By enabling objective monitoring of tissue oxygenation and perfusion dynamics, this technology is designed to support informed decision-making,” stated Casey Boutwell, CEO of NIRSense, Inc., in the original announcement. This capability is especially vital in austere environments where access to advanced surgical facilities is delayed.

Forged in Military R&D

The technology arriving in Ukraine is not a repurposed civilian device. It carries a strong operational pedigree, born from years of dedicated development for the U.S. military. Founded in 2018 with the mission to “help protect American warfighters,” NIRSense has worked closely with the U.S. Department of War since 2019 on contracts for the Navy, Air Force, and U.S. Special Forces.

This extensive collaboration has focused on creating ruggedized, operational-quality physiological monitors that can function reliably in extreme conditions. Unlike standard hospital equipment, these devices are built to be waterproof, shock-resistant, and lightweight, capable of providing accurate readings despite vibrations during transport or on any skin tone. One notable example of the company's work includes the development of the NIRSense Aerie, a flight-optimized wearable system designed to monitor the cerebral oxygenation of military pilots during high G-force maneuvers—an environment where traditional monitoring often fails.

It is crucial to note that the donated systems are investigational prototypes and have not yet been cleared by the U.S. Food and Drug Administration (FDA) for commercial sale. NIRSense is actively conducting clinical research to support its FDA submission, and the data gathered from the frontlines in Ukraine will be an invaluable part of this process, providing real-world evidence of the device's performance under the most challenging conditions imaginable.

A Partnership for Impact and Data

The delivery and implementation of this advanced technology are being managed by Aspen Medical USA, a company with deep and established roots in supporting Ukraine's medical infrastructure. AMUSA’s role extends far beyond simple logistics. The organization has been instrumental in Ukraine for over three years, operating under a contract with the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) to assess wartime medical care and deliver training and capabilities.

For this initiative, AMUSA organized the engagement with the Ukraine Ministry of Defence, translated all technical protocols and user guides into Ukrainian, and is providing direct training to the medical teams who will use the devices. Furthermore, AMUSA will oversee the secure collection and transfer of case data back to NIRSense for analysis and ongoing device optimization. This creates a powerful feedback loop, where immediate aid contributes directly to refining a technology that can then be deployed more effectively in the future.

AMUSA's broader work in the region, which includes conducting trauma surgery symposia for Ukrainian surgeons and supporting the “Unbroken Program”—the nation's largest rehabilitation initiative—through its foundation, underscores the comprehensive nature of its commitment.

Shaping the Future of Combat Medicine

This deployment is set to have implications that reach far beyond the current conflict. The war in Ukraine, a large-scale combat operation unlike the counterinsurgency campaigns of recent decades, is generating unprecedented data and lessons for military medicine. The performance of the NIRSense monitors will be closely watched by NATO and allied military medical planners.

Data on tissue viability during prolonged casualty care can directly inform and potentially rewrite medical doctrine on tourniquet management and evacuation strategies. The successful use of rugged, portable NIRS technology could establish a new standard of care, ensuring that forward-deployed medics have tools that provide hospital-quality data in pre-hospital settings.

As Ethan Bond, President of Aspen Medical USA, noted, the joint effort seeks to “ensure that forward-deployed casualty-care teams have access to the best available monitoring tools.” The lessons learned will not only strengthen Ukrainian medical resilience but also enhance the interoperability of trauma-care technologies among allied forces, better preparing them for future crises. This collaboration serves as a powerful model for leveraging defense innovation for humanitarian impact, accelerating the adoption of life-saving technologies in military trauma systems, expeditionary medicine, and civilian disaster response globally. The data from Ukraine's frontlines today will help save lives on battlefields and in disaster zones tomorrow.